Rush University Medical Center 3rd Midwest Cellular Conference Treatment Options for Advanced Hematologic Malignancies 2024

Rush University Medical Center 3rd Midwest Cellular Conference Treatment Options for Advanced Hematologic Malignancies 2024

 Include: 16 videos, size: 4.5 GB

Target Audience: hematologists, medical oncologists, pharmacists, fellows and residents

Information:

This program is designed to meet the educational needs of hematologists, medical oncologists, pharmacists, fellows and residents, APP’s, oncology nurses and other healthcare professionals committed to the field of cellular treatment options for advanced hematologic malignancies.

LEARNING OBJECTIVES

Following participation in this activity, learners will:

1. Discuss individualized treatment options for high-risk patients with plasma cell diseases (multiple myeloma (MM), amyloidosis), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL),non-Hodgkin Lymphoma (NHL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and aplastic anemia (AA).

2. Include autologous or allogeneic HCT and/or CAR-T cell therapy in treatment plans for patients with various refractory (advanced) hematologic malignancies.

3. Manage potential complications resulting from autologous or allogeneic HCT and/or CAR-T cell therapy.

4. Utilize newer chemotherapeutic treatment options in conjunction with HCT and CAR-T cell therapy for patients with various refractory (advanced) hematologic malignancies.

 Topics:

• Advancements in Richter’s Transformation- Novel Agents and Cellular Therapies.mp4
• Allo-HSCT Conditioning Regimens- Current Status and Future Directions.mp4
• BCMA & Beyond- Novel Targets for Immunotherapy in MM.mp4
• Bone Marrow Failure- The Importance of Mutational Testing.mp4
• CAR-T vs. Bispecific Antibodies in RR MM- Insights and Future Directions.mp4
• Cellular Therapy Strategies for Persistent Disease After Induction for B-ALL.mp4
• Challenges and Treatment Strategies in Advanced Stage Hodgkin Lymphoma.mp4
• High-Risk Myeloma- Updates in Defining and Managing.mp4
• Is Post-HSCT Maintenance the SOC for AML..mp4
• Management of Viral Infections Post-Transplant- CMV, EBV, and HHV-6.mp4
• Off the Shelf CARs for DLBCL- Myths and Facts.mp4
• Optimal Timing of CAR T-Cell Therapies in MCL- Cellular Therapy and Beyond.mp4
• Selection and Sequencing of Chronic GVHD Therapy.mp4
• The Role of SCT Amidst Emerging Therapies in the Treatment of AL Amyloidosis.mp4
• Transplant-Associated TMA- Challenges and Current Treatment Options.mp4
• What is New in AML- Risk Classification, Germline Mutations, and Targeted Therapies.mp4